Integrating chemoradiotherapy and nivolumab in advanced cervical cancer: two case reports

Background: Cervical cancer is the fourth most common cancer among women globally, with high recurrence rates in locally advanced cases despite standard treatment with chemoradiotherapy and brachytherapy. Immune checkpoint inhibitors (ICIs), such as nivolumab, have shown promise in enhancing anti-tumor immunity, particularly when combined with conventional therapy. Emerging data suggest that integrating ICIs into treatment regimens for high-risk cervical cancer may improve survival and disease control. Cases: We present two cases highlighting this approach. A 77-year-old woman with clinical stage IIA cervical squamous cell carcinoma underwent radical hysterectomy with pT2a1N1M0 staging, followed by chemoradiotherapy and brachytherapy in 2021. One year later, recurrence in the para-aortic and iliac lymph nodes was detected and successfully treated with salvage radiation and concurrent chemo-immunotherapy using nivolumab. She achieved complete remission and remains disease-free at the latest follow-up. The second case involves a 39-year-old woman diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 cervical squamous cell carcinoma with human papillomavirus (HPV)-16 positivity. She received chemoradiotherapy, brachytherapy, and immunotherapy with nivolumab, achieving complete remission and HPV clearance. In December 2021, recurrence in the para-aortic lymph nodes was treated with additional radiation, chemotherapy, and ongoing nivolumab maintenance. A hysterectomy in 2023 for abnormal bleeding revealed no residual disease, and the patient continues to be disease-free. Conclusions: These cases illustrate the potential benefit of combining chemoradiotherapy with maintenance immunotherapy using ICIs. This strategy may enhance progression-free survival and achieve durable disease control in advanced or recurrent cervical cancer. However, challenges such as treatment-related toxicity and resistance must be addressed. Continued research is vital to refine therapeutic protocols, identify predictive biomarkers, and optimize patient selection to maximize the benefits of this evolving treatment paradigm.

Cervical cancer; Nivolumab; Immunotherapy; Recurrent disease; Concurrent chemoradiotherapy and immune checkpoint inhibitors

[1] Institute NC. Cancer stat facts: cervical cancer. 2021. Available at: https://seer.cancer.gov/statfacts/html/cervix.html (Accessed: 17 April 2024).

[2] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73: 17–48.

[3] Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Frontiers in Microbiology. 2019; 10: 3116.

[4] zur Hausen H. The search for infectious causes of human cancers: where and why (Nobel lecture). Angewandte Chemie. 2009; 48: 5798–5808.

[5] Chen YC, Chen YY, Su SY, Jhuang JR, Chiang CJ, Yang YW, et al. Projected time for the elimination of cervical cancer under various intervention scenarios: age-period-cohort macrosimulation study. JMIR Public Health and Surveillance. 2024; 10: e46360.

[6] Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the management of patients with cervical cancer. International Journal of Gynecological Cancer. 2018; 28: 641–655.

[7] Gennigens C, De Cuypere M, Hermesse J, Kridelka F, Jerusalem G. Optimal treatment in locally advanced cervical cancer. Expert Review of Anticancer Therapy. 2021; 21: 657–671.

[8] Grigsby PW, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt C, et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival. Gynecologic Oncology. 2020; 157: 639–643.

[9] Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, Streel S, Kridelka F, et al. Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open. 2022; 7: 100579.

[10] Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiotherapy and Oncology. 2016; 120: 428–433.

[11] Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduction and Targeted Therapy. 2024; 9: 126.

[12] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology. 2020; 20: 651–668.

[13] Krishna S, Ulrich P, Wilson E, Parikh F, Narang P, Yang S, et al. Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer. Cancer Research. 2018; 78: 6159–6170.

[14] Zhang L, Zhao Y, Tu Q, Xue X, Zhu X, Zhao KN. The roles of programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy. Current Medicinal Chemistry. 2021; 28: 893–909.

[15] Rice AE, Latchman YE, Balint JP, Lee JH, Gabitzsch ES, Jones FR. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Therapy. 2015; 22: 454–462.

[16] Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. The New England Journal of Medicine. 2021; 385: 1856–1867.

[17] Callahan MK, Odunsi K, Sznol M, Nemunaitis JJ, Ott PA, Dillon PM, et al. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. Journal of Clinical Oncology. 2017; 35: 3069.

[18] Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. Journal of Clinical Oncology. 2017; 35: 4035–4041.

[19] Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology. 2020; 157: 161–166.

[20] Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology. 2019; 37: 2825–2834.

[21] Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology. 2019; 37: 1470–1478.

[22] Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. Journal for Immunotherapy of Cancer. 2020; 8: e001126.

[23] Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncology. 2018; 4: e173776.

[24] Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, et al. Survival with cemiplimab in recurrent cervical cancer. The New England Journal of Medicine. 2022; 386: 544–555.

[25] Turinetto M, Lombardo V, Pisano C, Musacchio L, Pignata S. Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma. Expert Review of Anticancer Therapy. 2022; 22: 1039–1047.

[26] Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. Regression of chemotherapy-resistant polymerase ε (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clinical Cancer Research. 2016; 22: 5682–5687.

[27] Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. Journal of Clinical Oncology. 2017; 35: 2535–2541.

[28] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine. 2015; 372: 2509–2520.

[29] Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Science. 2019; 110: 2894–2904.

[30] Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecologic Oncology. 2019; 154: 314–322.

[31] NIH. Phase II study of atezolizumab + bevacizumab in endometrial cancer. 2018. Available at: https://clinicaltrials.gov/study/NCT03526432 (Accessed: 14 August 2023).

[32] Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, et al. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. The Journal for ImmunoTherapy of Cancer. 2022; 10: e004233.

[33] Kelkar SS, Prabhu VS, Zhang J, Corman S, Macahilig C, Rusibamayila N, et al. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States. Gynecologic Oncology Reports. 2022; 42: 101026.

[34] Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 2019; 20: 711–718.

[35] FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England Journal of Medicine. 2007; 356: 1915–1927.

[36] Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet. 2001; 358: 781–786.

[37] Logsdon MD, Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 1999; 43: 763–775.

[38] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of Clinical Oncology. 2008; 26: 5802–5812.

[39] Macdonald OK, Chen J, Dodson M, Lee CM, Gaffney DK. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. American Journal of Clinical Oncology. 2009; 32: 411–416.

[40] Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. Journal of Clinical Oncology. 2010; 28: 2108–2113.

[41] Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. International Journal of Gynecology & Obstetrics. 2006; 95: S43–S103.

[42] Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics. 2018; 143: 22–36.

[43] Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. Journal of Clinical Oncology. 2018; 36: 1548–1555.

[44] Carvalho HA, Mauro GP. History of radiotherapy in the treatment of uterine cervix cancer: an overview. Journal of the Brazilian Medical Association. 2023; 69: e2023S126.

[45] Wu F, Tang X, Zhang Y, Jiang L, Gao T, Huang Q, et al. The role of radiation therapy for metastatic cervical cancer. International Journal of Radiation Oncology, Biology, Physics. 2023; 117: e555.

[46] Pirš B, Škof E, Smrkolj V, Smrkolj Š. Overview of immune checkpoint inhibitors in gynecological cancer treatment. Cancers. 2022; 14: 631.

[47] Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, et al. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology. 2016; 5: e1085146.

[48] Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): randomized, double-blind, phase 3 clinical trial. The Lancet. 2024; 403: 1341–1350.

[49] Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. International Journal of Gynecological Cancer. 2020; 30: 1065–1070.

[50] Qi L, Li N, Lin A, Wang X, Cong J. Efficacy and safety of pembrolizumab on cervical cancer: a systematic review and single-arm meta-analysis. Frontiers in Oncology. 2022; 12: 910486.

[51] Abu-Rustum NR, Neubauer N, Sonoda Y, Park KJ, Gemignani M, Alektiar KM, et al. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecologic Oncology. 2008; 111: 261–264.

[52] Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, et al. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nature Communications. 2023; 14: 3698.

[53] Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology. 2021; 39: 4073–126.

[54] O’Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology. 2021; 163: 274–280.

[55] Oaknin A, Moore K, Meyer T, López-Picazo González J, Devriese LA, Amin A, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. The Lancet Oncology. 2024; 25: 588–602.

[56] Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation. 2017; 127: 2930–2940.

[57] Coleman S, Xie M, Tarhini AA, Tan AC. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Molecular Carcinogenesis. 2023; 62: 77–89.

[58] Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019; 176: 1248–1264.

[59] Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications. 2020; 11: 5439.

[60] Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, et al. Clinical and genetic landscape of treatment naive cervical cancer: alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. EBioMedicine. 2019; 43: 253–260.

[61] Fogt S, Andabekov T, Shamsutdinova Y, Dvorkin M, Artamonova E, Chistyakov V, et al. Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer. Journal of Clinical Oncology. 2023; 41: 5536–5536.

[62] Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. European Journal of Cancer. 2021; 149: 222–232.

[63] Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduction and Targeted Therapy. 2023; 8: 320.

[64] Mo DC, Huang JF, Luo PH, Huang SX, Wang HL. Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: a meta-analysis of randomized controlled trials. Medicine. 2022; 101: e30830.

[65] Petre I, Vernic C, Petre I, Vlad CS, Sipos SI, Bordianu A, et al. Systematic review on the effectiveness and outcomes of nivolumab treatment schemes in advanced and metastatic cervical cancer. Diseases. 2024; 12: 77.

[66] Devabhaktuni S, Singh A, Georgy JT, Antonisamy J, Thumaty DB, John AO. 286MO efficacy of low dose nivolumab in recurrent/metastatic cervical cancer. Annals of Oncology. 2023; 34: S1585.

[67] Ray-Coquard IL, Kaminsky-Forrett MC, Ohkuma R, De Montfort A, Joly F, Treilleux I, et al. In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study. Journal of Clinical Oncology. 2023: 41: 5501.